RA Capital’s Latest Move In Alcobra Ltd (ADHD) Coming Off Hefty Second Quarter Gains

During the March quarter, RA Capital decreased its stake in Dyax Corp. (NASDAQ:DYAX) by 14% to 4.21 million shares valued at $70.50 million. It was the fund’s second-largest equity holding and represented about 7.0% of its portfolio. The stock is up by almost 88% on a year-to-date basis, with the major part of the hike coming in early April as DX-2930, a drug for treating hereditary angioedema, posted promising early stage data. This led to a 58.15% gain for the stock in the second quarter. Stuart Weisbrod‘s Iguana Healthcare Management is the largest stockholder of Dyax Corp. (NASDAQ:DYAX) within our database, holding some 150,000 shares valued at $2.51 million.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)’s stock has risen by more than 24% year-to-date and it is RA Capital’s third-largest equity holding with some 6.93 million shares valued at $62.55 million. During the second trimester the stock posted more than 65% gains.  Among the funds that we track, Baker Bros. is the largest stockholder of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), owning some 10.48 million shares valued at $94.62 million.

RA Capital increased its exposure in Xencor Inc (NASDAQ:XNCR) by 55% during the first three months to 2.15 million shares valued at $32.93 million. The move has paid off, as the stock appreciated by more than 43% during the April-June quarter. Aside from RA Capital, Joseph Edelman’s Perceptive Advisors is the largest investor of Xencor Inc (NASDAQ:XNCR) among those that we keep track of, holding some 2.15 million shares valued at $32.93 million.

Disclosure: None